Cardiovascular Outcomes in Systemic Lupus Erythematosus
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
Data on long-term cardiovascular outcomes in systemic lupus erythematosus (SLE) are sparse.

This study sought to examine the long-term risk and prognosis associated with cardiovascular outcomes, including heart failure (HF), in patients with SLE.

Using Danish administrative registries, risks of outcomes were compared between SLE patients and age-, sex-, and comorbidity-matched control subjects from the background population (matched 1:4). Furthermore, mortality following HF diagnosis was compared between SLE patients developing HF and age- and sex-matched non-SLE control subjects with HF (matched 1:4).

-- A total of 3,411 SLE patients (median age: 44.6 years [25th to 75th percentile: 31.9 to 57.0 years]; 14.1% men) were matched with 13,644 control subjects.

--The median follow-up was 8.5 years (25th to 75th percentile: 4.0 to 14.4 years).

-- Absolute 10-year risks of outcomes were: HF, 3.71% for SLE patients, 1.94% for control subjects; atrial fibrillation, 4.35% for SLE patients, 2.82% for control subjects; ischemic stroke, 3.75% for SLE patients, 1.92% for control subjects; myocardial infarction, 2.17% for SLE patients, 1.49% for control subjects; venous thromboembolism, 6.03% for SLE patients, 1.68% for control subjects; and the composite of implantable cardioverter-defibrillator implantation/ventricular arrhythmias/cardiac arrest, 0.89% for SLE patients, 0.30% for control subjects.

-- SLE with subsequent HF was associated with higher mortality compared with HF without SLE.

Conclusively, SLE patients had a higher associated risk of HF and other cardiovascular outcomes compared with matched control subjects. Among patients developing HF, a history of SLE was associated with higher mortality.